A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®-or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants

Trial Profile

A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®-or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2017

At a glance

  • Drugs HIV vaccine-vCP2438 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top